TNFSF10 and prostate cancer: In the presence of TRAIL, the viability of the PC3 cells was significantly higher than that of the C2KD-1 cells (Fig. 4C), indicating that C2GnT-expressing prostate cancer cells are more resistant to TRAIL than are C2GnT-deficient cells.